Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma

C. Ortolani, F. Capsoni, M. Restuccia, E. Pastorello, P. S. Riboldi, M. Zocchi, C. Zanussi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Neutrophil chemotactic activity (NCA) following oral challenge with aspirin (ASA) was determined in ASA-intolerance asthmatic subjects, and in ASA-tolerant asthmatic and normal subjects. There was a statistically significant fall in FEV1 and a rise in NCA (P <0.01) following challenge in the ASA-sensitive subjects compared with that of the ASA-tolerant subjects and normal controls. No significant difference was observed between the latter two groups. The chemotactic factor identified in this study had a molecular weight greater than 150,000 which is consistent with NCF-A (neutrophil chemotactic factor of anaphylaxis). The ASA-induced fall in FEV1 and rise in NCA was further studied in three of the ASA-intolerant asthmatic subjects, with and without pretreatment with inhaled sodium cromoglycate. In these subjects, the drug inhibited both the oral ASA-induced bronchoconstriction and the increase in neutrophil chemotactic activity. These results suggest that ASA-induced asthma involves mediator release from mast cells, as shown by the increase in NCA following ASA challenge and the protective effect of sodium cromoglycate which is considered to inhibit mast-cell degranulation.

Original languageEnglish
Pages (from-to)443-452
Number of pages10
JournalClinical Allergy
Volume14
Issue number5
Publication statusPublished - 1984

Fingerprint

Aspirin Induced Asthma
Anaphylaxis
Interleukin-8
Neutrophils
Cromolyn Sodium
Mast Cells
Cell Degranulation
Bronchoconstriction
Chemotactic Factors
Aspirin
Asthma
Molecular Weight
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Ortolani, C., Capsoni, F., Restuccia, M., Pastorello, E., Riboldi, P. S., Zocchi, M., & Zanussi, C. (1984). Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma. Clinical Allergy, 14(5), 443-452.

Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma. / Ortolani, C.; Capsoni, F.; Restuccia, M.; Pastorello, E.; Riboldi, P. S.; Zocchi, M.; Zanussi, C.

In: Clinical Allergy, Vol. 14, No. 5, 1984, p. 443-452.

Research output: Contribution to journalArticle

Ortolani, C, Capsoni, F, Restuccia, M, Pastorello, E, Riboldi, PS, Zocchi, M & Zanussi, C 1984, 'Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma', Clinical Allergy, vol. 14, no. 5, pp. 443-452.
Ortolani C, Capsoni F, Restuccia M, Pastorello E, Riboldi PS, Zocchi M et al. Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma. Clinical Allergy. 1984;14(5):443-452.
Ortolani, C. ; Capsoni, F. ; Restuccia, M. ; Pastorello, E. ; Riboldi, P. S. ; Zocchi, M. ; Zanussi, C. / Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma. In: Clinical Allergy. 1984 ; Vol. 14, No. 5. pp. 443-452.
@article{985c5a45e143474eb3645740b94d5841,
title = "Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma",
abstract = "Neutrophil chemotactic activity (NCA) following oral challenge with aspirin (ASA) was determined in ASA-intolerance asthmatic subjects, and in ASA-tolerant asthmatic and normal subjects. There was a statistically significant fall in FEV1 and a rise in NCA (P <0.01) following challenge in the ASA-sensitive subjects compared with that of the ASA-tolerant subjects and normal controls. No significant difference was observed between the latter two groups. The chemotactic factor identified in this study had a molecular weight greater than 150,000 which is consistent with NCF-A (neutrophil chemotactic factor of anaphylaxis). The ASA-induced fall in FEV1 and rise in NCA was further studied in three of the ASA-intolerant asthmatic subjects, with and without pretreatment with inhaled sodium cromoglycate. In these subjects, the drug inhibited both the oral ASA-induced bronchoconstriction and the increase in neutrophil chemotactic activity. These results suggest that ASA-induced asthma involves mediator release from mast cells, as shown by the increase in NCA following ASA challenge and the protective effect of sodium cromoglycate which is considered to inhibit mast-cell degranulation.",
author = "C. Ortolani and F. Capsoni and M. Restuccia and E. Pastorello and Riboldi, {P. S.} and M. Zocchi and C. Zanussi",
year = "1984",
language = "English",
volume = "14",
pages = "443--452",
journal = "Clinical Allergy",
issn = "0009-9090",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma

AU - Ortolani, C.

AU - Capsoni, F.

AU - Restuccia, M.

AU - Pastorello, E.

AU - Riboldi, P. S.

AU - Zocchi, M.

AU - Zanussi, C.

PY - 1984

Y1 - 1984

N2 - Neutrophil chemotactic activity (NCA) following oral challenge with aspirin (ASA) was determined in ASA-intolerance asthmatic subjects, and in ASA-tolerant asthmatic and normal subjects. There was a statistically significant fall in FEV1 and a rise in NCA (P <0.01) following challenge in the ASA-sensitive subjects compared with that of the ASA-tolerant subjects and normal controls. No significant difference was observed between the latter two groups. The chemotactic factor identified in this study had a molecular weight greater than 150,000 which is consistent with NCF-A (neutrophil chemotactic factor of anaphylaxis). The ASA-induced fall in FEV1 and rise in NCA was further studied in three of the ASA-intolerant asthmatic subjects, with and without pretreatment with inhaled sodium cromoglycate. In these subjects, the drug inhibited both the oral ASA-induced bronchoconstriction and the increase in neutrophil chemotactic activity. These results suggest that ASA-induced asthma involves mediator release from mast cells, as shown by the increase in NCA following ASA challenge and the protective effect of sodium cromoglycate which is considered to inhibit mast-cell degranulation.

AB - Neutrophil chemotactic activity (NCA) following oral challenge with aspirin (ASA) was determined in ASA-intolerance asthmatic subjects, and in ASA-tolerant asthmatic and normal subjects. There was a statistically significant fall in FEV1 and a rise in NCA (P <0.01) following challenge in the ASA-sensitive subjects compared with that of the ASA-tolerant subjects and normal controls. No significant difference was observed between the latter two groups. The chemotactic factor identified in this study had a molecular weight greater than 150,000 which is consistent with NCF-A (neutrophil chemotactic factor of anaphylaxis). The ASA-induced fall in FEV1 and rise in NCA was further studied in three of the ASA-intolerant asthmatic subjects, with and without pretreatment with inhaled sodium cromoglycate. In these subjects, the drug inhibited both the oral ASA-induced bronchoconstriction and the increase in neutrophil chemotactic activity. These results suggest that ASA-induced asthma involves mediator release from mast cells, as shown by the increase in NCA following ASA challenge and the protective effect of sodium cromoglycate which is considered to inhibit mast-cell degranulation.

UR - http://www.scopus.com/inward/record.url?scp=0021177996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021177996&partnerID=8YFLogxK

M3 - Article

C2 - 6435908

AN - SCOPUS:0021177996

VL - 14

SP - 443

EP - 452

JO - Clinical Allergy

JF - Clinical Allergy

SN - 0009-9090

IS - 5

ER -